Ex Vivo High-Throughput Assay for Vaginal Community Post-menopausal Women

Vaginal swabs will be collected from post-menopausal women (5 women vaginal pH ≤4.5 and 5 women with vaginal pH≥5.5), aged 45 - 75, with at least 12 months of amenorrhea. Enough women will be screened to ensure five women for each pH range.

Using a speculum, the mid lateral vaginal wall is made visible, samples will be collected by the physician or nurse using a flocked swab. After collection, vaginal swabs will be stored immediately in adequate liquid medium at 4ºC and will be transported to the lab within 7 hours after sampling for further storage and culture of the material.

The vaginal microbiota of post-menopausal women with a vaginal pH of ≤ 4.5 and ≥ 5.5 will be characterized and compared using 16S ribosomal ribonucleic acid (rRNA) sequencing. In additional, optimal conditions for cultivation and storage of the vaginal microbiota will be examined for use in assays mimicking the vaginal microbial community of postmenopausal women.

Inclusion criteria

• Agree to study design (signed informed consent)
• Post-menopausal women
• Vaginal pH ≤4.5 or pH ≥5.5
• At least 12 months of amenorrhea
• Age ≥45 and ≤75
• Currently in a mutually monogamous sexual relationship or not sexually active;
• Sexually abstinent 48 hours prior to visit.
• Willing and capable of following all study instructions; and
• Good general health.

Exclusion criteria

• Vaginal pH between >4.5 and <5.5
• Use of topical estrogen containing product 1 week prior to enrollment
• Use of vaginal lubricants, douches, or any products applied vaginally during the week prior to the first visit
• Use of systemic estrogen therapy or products 6 months prior to inclusion
• Use of a vaginal pessary during the week prior to the visit
• Excessive alcohol usage (>4 consumptions/day or >20 consumptions/week)
• Drug usage within past 2 years
• A history or currently undergoing immunosuppressive drug therapy, chemotherapy, or radiation therapy
• A medical condition which might compromise immune system functions (such as cancer, leucopenia, HIV-positive, or organ transplant)
• Antibiotics and/or anti-fungal medication use within the last four (4) weeks
• Induced menopause due to surgical or medical interventions, such as bilateral oophorectomy, hysterectomy, chemotherapy or radiation treatment
• Currently diagnosed with or being treated for a genital infection or urinary tract infection, subjects who had any vaginal infection one month prior to the screening will be excluded
• Individuals with a sexually transmitted disease (self-reported or detected by the Principal Investigator)
• At enrollment, have any social or medical condition, or psychiatric illness that, in the opinion of the Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
• Participation in a clinical trial involving an investigational product/device within the past three months; subjects who are scheduled to participate in another clinical study concurrently.